5-MeO-DMT vs DMT: What Is the Difference?

5-MeO-DMT and N,N-DMT are related tryptamines, but they are different molecules and should not be treated as interchangeable. 5-MeO-DMT is also called mebufotenin. N,N-DMT is commonly shortened to DMT. Bufotenine, also called 5-HO-DMT, is a third molecule.

Both 5-MeO-DMT and N,N-DMT interact with multiple serotonin-receptor systems, including 5-HT1A and 5-HT2A, but their binding and signaling profiles differ. Laboratory receptor findings alone do not explain every difference in human experience.

Reports of inhaled N,N-DMT often emphasize geometric imagery, vivid colors, altered environments, unusual scenes or apparent beings. Reports and controlled studies involving 5-MeO-DMT more often emphasize major changes in self-boundaries, unity, time, emotion and bodily sensation.

These are patterns from separate datasets, not universal rules or proof from a direct controlled comparison. Either molecule can produce fear, confusion, memory gaps, perceptual changes or an experience that differs from expectations.

It is inaccurate to say that 5-MeO-DMT never causes visuals. Controlled studies have documented changes in visual perception, although elaborate imagery may be less central in many 5-MeO-DMT reports than in reports of N,N-DMT.

Individual experiences vary. Darkness, brightness, patterns, colors, vivid scenes or minimal imagery may occur. The presence or absence of visuals does not establish safety, therapeutic value or the importance of an experience.

Route and formulation must be named when comparing duration. In a controlled study of vaporized GH001, the estimated 5-MeO-DMT experience averaged approximately 14 to 18 minutes. The 2026 phase 2b trial reported median psychoactive-effect durations of approximately 9 to 14 minutes across its tested regimens.

Controlled intravenous N,N-DMT studies found effects peaking within about two minutes and resolving within roughly 12 to 30 minutes, depending on the study and dose. A retrospective analysis of inhaled N,N-DMT reports found a median duration of approximately 10 minutes, but those reports were uncontrolled.

Ayahuasca has a different formulation and commonly produces effects lasting several hours.

There is no validated dose-equivalence formula or controlled head-to-head comparison that translates the intensity of one molecule into the other.

“Stronger” could refer to dose, onset, peak intensity, visuals, ego dissolution, emotion, physical effects, duration, fear or medical risk. “Better” depends on personal beliefs and goals and is not a scientific safety or effectiveness measure. Neither molecule has been established as universally safer, more therapeutic or more meaningful.

“Bufo” commonly refers to dried defensive secretion from the Sonoran Desert toad, Incilius alvarius.

Recent chemical analysis found 5-MeO-DMT along with several other tryptamine-derived compounds in sampled secretions. A biological secretion should therefore not be treated as identical to a purified molecule.

Synthetic 5-MeO-DMT can be produced as a defined molecule, while pharmaceutical research uses standardized formulations with composition controls. This does not make an unverified synthetic product automatically safe. Clinical findings involving standardized pharmaceutical mebufotenin cannot automatically be transferred to toad secretion.

Source, composition, purity, animal welfare, conservation and ceremonial meaning are separate considerations.

Ayahuasca is neither 5-MeO-DMT nor simply another name for inhaled DMT. It is a family of preparations commonly containing N,N-DMT together with beta-carboline monoamine oxidase inhibitors such as harmine, harmaline and tetrahydroharmine.

MAO inhibition changes how N,N-DMT is metabolized and makes a much longer oral experience possible. Botanical preparations can vary in composition, so ayahuasca research should not be generalized to every preparation.

Combining 5-MeO-DMT with an MAOI is not equivalent to traditional ayahuasca pharmacology. In animal studies, MAO-A inhibition increased and prolonged 5-MeO-DMT exposure, while harmaline markedly intensified 5-MeO-DMT-induced hyperthermia.

Human safety for this combination has not been established. It should not be presented as a routine or interchangeable combination. This page does not provide instructions for combining controlled substances.

A trial involving one molecule, formulation, population or condition answers a narrow question. It does not establish the effects of another molecule or a ceremony.

A randomized phase 2b trial published in March 2026 studied inhaled synthetic mebufotenin, called GH001, in 81 carefully selected adults with treatment-resistant depression under medical supervision. Its results apply to that formulation, protocol, population and clinical setting.

The trial does not validate N,N-DMT, ayahuasca, toad secretion or retreat use. Findings involving N,N-DMT or ayahuasca likewise should not be presented as evidence for 5-MeO-DMT.

Both molecules can produce rapid changes in awareness, intense psychological or physical reactions, disorientation, impaired coordination and difficulty communicating. The relevant risks depend on the exact substance, formulation, route, health history, medications, other substances, setting and available support.

Published trials used narrow eligibility criteria and extensive medical and psychiatric screening. Their exclusions identify important evidence gaps but should not be turned into universal online medical rules.

Never stop or alter prescribed medication without consulting the prescriber responsible for that treatment. See the full safety guide for contraindications, medication interactions and emergency warning signs.

Ask:

• What exact substance and formulation are being discussed?
• How was its identity and composition verified?
• Who reviews medical and psychiatric history?
• Who reviews prescriptions, supplements and substance use?
• Which conditions require exclusion or medical referral?
• What consent rules apply to touch, recording and privacy?
• What training and emergency planning are in place?
• How long are participants observed before leaving?
• Is safe transportation required?
• What support and professional referrals are available afterward?
• Do research claims identify the exact molecule, formulation, population and measured outcome?